Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice.

Kim HY, Alarcon C, Pourteymour S, Wergedal JE, Mohan S.

Am J Physiol Endocrinol Metab. 2013 Mar 1;304(5):E531-7. doi: 10.1152/ajpendo.00408.2012. Epub 2013 Jan 8.

2.

Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation.

Linares GR, Brommage R, Powell DR, Xing W, Chen ST, Alshbool FZ, Lau KH, Wergedal JE, Mohan S.

J Bone Miner Res. 2012 Jul;27(7):1553-65. doi: 10.1002/jbmr.1600.

3.

Effects of JSOG-6 on protection against bone loss in ovariectomized mice through regulation of osteoblast differentiation and osteoclast formation.

Chung HJ, Cho L, Shin JS, Lee J, Ha IH, Park HJ, Lee SK.

BMC Complement Altern Med. 2014 Jun 6;14:184. doi: 10.1186/1472-6882-14-184.

4.

Critical role of beta3 integrin in experimental postmenopausal osteoporosis.

Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV.

J Bone Miner Res. 2005 Dec;20(12):2116-23. Epub 2005 Jul 25.

5.

Deficiency of adiponectin protects against ovariectomy-induced osteoporosis in mice.

Wang F, Wang PX, Wu XL, Dang SY, Chen Y, Ni YY, Gao LH, Lu SY, Kuang Y, Huang L, Fei J, Wang ZG, Pang XF.

PLoS One. 2013 Jul 2;8(7):e68497. doi: 10.1371/journal.pone.0068497. Print 2013.

6.

Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss.

Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA.

J Bone Miner Res. 2006 May;21(5):695-702.

7.

Biglycan deficiency interferes with ovariectomy-induced bone loss.

Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen XD, Poulsen HS, Young MF, Heegaard AM.

J Bone Miner Res. 2003 Dec;18(12):2152-8.

8.

Inhibition of substance P signaling aggravates the bone loss in ovariectomy-induced osteoporosis.

Zheng XF, Zhao ED, He JY, Zhang YH, Jiang SD, Jiang LS.

Prog Biophys Mol Biol. 2016 Nov;122(2):112-121. doi: 10.1016/j.pbiomolbio.2016.05.011. Epub 2016 May 26.

PMID:
27237582
9.

Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss.

Lindberg MK, Svensson J, Venken K, Chavoshi T, Andersson N, Movérare Skrtic S, Isaksson O, Vanderschueren D, Carlsten H, Ohlsson C.

Bone. 2006 Jan;38(1):85-92. Epub 2005 Oct 27.

PMID:
16257281
10.

Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.

Mun SH, Won HY, Hernandez P, Aguila HL, Lee SK.

J Bone Miner Res. 2013 Apr;28(4):948-59. doi: 10.1002/jbmr.1787.

11.

Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.

Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S.

J Bone Miner Res. 2007 Jun;22(6):849-59.

12.

Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis.

Xing W, Liu J, Cheng S, Vogel P, Mohan S, Brommage R.

J Bone Miner Res. 2013 Sep;28(9):1962-74. doi: 10.1002/jbmr.1935.

13.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ.

J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109.

15.

Adenosine A(2A) receptor ligation inhibits osteoclast formation.

Mediero A, Kara FM, Wilder T, Cronstein BN.

Am J Pathol. 2012 Feb;180(2):775-86. doi: 10.1016/j.ajpath.2011.10.017. Epub 2011 Nov 30.

16.

Short- and long-term effects of calcium and exercise on bone mineral density in ovariectomized rats.

Gala J, Díaz-Curiel M, de la Piedra C, Calero J.

Br J Nutr. 2001 Oct;86(4):521-7.

PMID:
11591240
17.

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.

Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD.

Bone. 1995 Nov;17(5):491-6.

PMID:
8579962
18.

Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.

Kameda Y, Takahata M, Mikuni S, Shimizu T, Hamano H, Angata T, Hatakeyama S, Kinjo M, Iwasaki N.

Bone. 2015 Feb;71:217-26. doi: 10.1016/j.bone.2014.10.027. Epub 2014 Nov 8.

PMID:
25460183
19.

Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.

Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E.

Bone. 2008 May;42(5):950-9. doi: 10.1016/j.bone.2008.01.010. Epub 2008 Feb 8.

PMID:
18337202
20.

Shark protein improves bone mineral density in ovariectomized rats and inhibits osteoclast differentiation.

Uehara K, Takahashi A, Watanabe M, Nomura Y.

Nutrition. 2014 Jun;30(6):719-25. doi: 10.1016/j.nut.2013.11.005. Epub 2013 Nov 22.

PMID:
24800672

Supplemental Content

Support Center